瑞替普酶治疗急性心肌梗死疗效观察

目的 观察瑞替普酶(r-PA)和尿激酶(UK)溶栓治疗急性心肌梗死(AMD的疗效及安全性.方法 将65例AMI患者随机分为两组:r-PA组32例,r-PA 36 mg分两次静脉推注,每次18 mg,间隔30 min;UK组33例,以UK 150万U 30 rnin静脉滴注完.比较两组的开通率、开通时间及出血等不良反应的发生率.结果 两组患者的血管开通率分别为81.25％和57.58％,开通时间分别为(1.54±0.65)h和(2.01±0.73)h(P＜0.05)；两组出血等不良反应发生率差异无统计学意义(P＞0.05).结论 与UK相比,r-PA静脉溶栓治疗AMI能更早地开通梗死相关血管,有较高的血管开通率,是一种安全有效的溶栓药物.

Clinical observation on the effect of reteplase as thrombolytics in the treatment of patients with acute myocardial infarction

Objective To analysis the clinical efficacy and safety of intravenous thrombolytic therapy using reteplase(r-PA) or urokinase for treating patients with acute myocardial infarction(AMI).Methods 65 patients with AMI were randomized to receive either reteplase(r-PA group,n=32) or urokinase(UK group,n=33).36 mg reteplsae was administered intravenously,18 mg each injection for two times with 30 minutes interval.Urokinase was administered as 1.5 million units by intravenous dropping within 30 minutes.The patency rate,time of patency,the incidence of bleeding complications and other adverse reactions were compared between the two groups.Results The patency rate was significantly higher in the r-PA group than in the UK group(81.25% vs 57.58%),while the time of the patency was significantly shorter in the r-PA group than in the UK group,(1.54±0.65) h vs(2.01±0.73) h.There was no statistically significant difference in the incidence of bleeding complications between the two groups(P>0.05).Conclusion Reteplase is an effective,reliable and safe thrombolytic agent in the treatment of acute myocardial infarction.